Celgene’s psoriasis drug works in study but can it compete?
This article was originally published in Scrip
Executive Summary
Celgene’s experimental psoriasis drug apremilast works and is relatively safe, according to a pivotal trial. However, the drug was shown to be a little less effective than an earlier study suggested, which casts doubts on the company’s bullish forecast for potential sales.